MAHINDRANAUTH DEONARINE: Open Payments
NPI 1841253127 · LANHAM, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$457 in 23 payments from 3 companies in 2025. Trend: 2023 $279 · 2024 $306 · 2025 $457
Food & beverage: $457
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 10 | $230 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $190 |
| Alkermes, Inc. | 2 | $37 |
Products named: REXULTI, CAPLYTA, ARISTADA.
Industry payments across MD — which companies pay providers there.
